Last Name

Emily Mason-Osann

TitlePre-Doctoral Trainee
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences
ORCID ORCID Icon0000-0003-0890-6440
 Research Expertise & Professional Interests
I am a graduate student studying the Alternative Lengthening of Telomeres (ALT) pathway

 Self-Described Keywords
  • Cancer
  • Cancer biology
  • Therapeutic development
  • Telomere
  • Alternative Lengthening of Telomeres
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mason-Osann E, Hollevoet K, Niederfellner G, Pastan I. Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Sci Rep. 2015; 5:10832. PMID: 26111884.
    View in: PubMed
  2. Hollevoet K, Mason-Osann E, Müller F, Pastan I. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. PLoS One. 2015; 10(3):e0122462. PMID: 25803818.
    View in: PubMed
  3. Manning ML, Mason-Osann E, Onda M, Pastan I. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice. J Immunol. 2015 Feb 15; 194(4):1695-701. PMID: 25560410.
    View in: PubMed
  4. Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther. 2014 Aug; 13(8):2040-9. PMID: 24928849.
    View in: PubMed
Emily's Networks
Click the "See All" links for more information and interactive visualizations!
Similar BU People